ProQR Therapeutics (PRQR)
Develops Axiomer RNA-editing medicines, led by AX-0810 for cholestatic diseases.
Something off on this page? Send us feedback.
Develops RNA-editing medicines through the Axiomer platform, with AX-0810 in a first-in-human study for cholestatic diseases. The clinical-stage company shifted away from inherited-retinal-disease programs and maintains a liver and nervous-system collaboration with Eli Lilly.
Develops RNA-editing medicines using Axiomer, a platform that employs endogenous ADAR machinery to make targeted single-nucleotide RNA edits. The platform supports programs intended to correct or modulate RNA, following the 2022 shift away from inherited-retinal-disease programs.
AX-0810, an NTCP-targeting editing oligonucleotide for cholestatic diseases, leads the internal pipeline in a first-in-human Phase 1 study. AX-0811 is in late non-clinical development, and AX-0422 targets Hurler syndrome in non-clinical development.
Based in Leiden, the Netherlands, with a U.S. office in Cambridge, Massachusetts, the clinical-stage organization also works with Eli Lilly on potential medicines for genetic disorders in the liver and nervous system. Progress depends on clinical-trial execution and regulatory interactions.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | Bank of America Securities | Initiate | Buy | |||
| Jun 25, 2026 | Chardan Capital | Target | $2 | $3 | ||
| Oct 29, 2024 | Raymond James | Upgrade | Outperform | Strong Buy |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $135.9M · Total debt $15.3M · Total assets $154.9M · Shareholders' equity $92.2M
- Revenue
- $10.3M
- Operating income
- —
- Net income
- −$10.3M
Reported in EUR, converted at the latest exchange rate
No dividends on record.
| Institutions69 holders · as of Mar 31, 2026 | 33.30% | 35.09M ADS | |
| Insiders6 holders · as of Aug 3, 2026 | 2.33% | 2.46M ADS | |
| Otherremainder | 64.37% | 67.82M ADS |
105.36M ADS as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Adage Capital Management, L.P.Institution | 6.27% | 6.60M | 13Gfiled Aug 12, 2025 ↗ |
Adage Capital Partners GP, L.L.C.Institution | 5.94% | 6.25M ADS | 13Fas of Mar 31, 2026 |
Privium Fund Management B.V.Institution | 5.19% | 5.47M ADS | 13Fas of Mar 31, 2026 |
Abrdn PLCInstitution | 3.15% | 3.32M ADS | 13Fas of Mar 31, 2026 |
Affinity Asset Advisors, LLCInstitution | 2.33% | 2.45M ADS | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 31, 2026 | Daniel Anton de Boer | director, officer: Chief Executive Officer | +200,000 | $1.77 |
| Jul 17, 2026 | Bart Filius | director | +150,000 | $1.72 |
| Jul 9, 2026 | Daniel Anton de Boer | director, officer: Chief Executive Officer | +150,000 | $1.74 |
| Jul 7, 2026 | Daniel Anton de Boer | director, officer: Chief Executive Officer | +150,000 | $1.59 |
| Jun 26, 2026 | Bart Filius | director | +150,000 | $1.54 |
- Wave Life Sciences
ADAR RNA editing and GalNAc liver medicines
- Korro Bio
OPERA-based ADAR editing and GalNAc liver programs
- Mirum Pharmaceuticals
Rare cholestatic-liver medicines and IBAT inhibition
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ProQR Therapeutics | $2.30 | +6.73% | $226.4M | — | — | 10.5 | +122.6% |
| Wave Life Sciences | $4.83 | −0.82% | $961.6M | — | — | 14.7 | −73.9% |
| Korro Bio | $12.25 | +2.68% | $119.1M | — | — | 50.0 | +2.7% |
| Mirum Pharmaceuticals | $99.81 | +1.49% | $6.09B | — | — | 9.8 | +37.9% |
| Median | — | — | 14.7 | +2.7% |